All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
EHA 2024: Topline findings of the TUD-APOLLO-064 trial and their potential clinical implications
Featured
Bookmark this article
During the European Hematology Association (EHA) 2024 Hybrid Congress, the AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What were the topline findings of the TUD-APOLLO-064 trial and their potential clinical implications?
EHA 2024: Topline findings of the TUD-APOLLO-064 trial and their potential clinical implications
Professor Platzbecker shares the study design and latest data from the TUD-APOLLO-064 trial of arsenic trioxide combined with all-trans retinoic acid (ATRA-ATO) and idarubicin vs standard ATRA and anthracycline-based chemotherapy (ATRA-CHT) for the treatment of newly diagnosed, high-risk acute promyelocytic leukemia (APL). Platzbecker discusses the promising event-free survival data favoring the novel combination, without an increase in toxicities or mortality compared with the comparator arm. Platzbecker closes by providing his insight on how these data may influence the future treatment paradigm for patients with high-risk APL.
Key data and learnings from Professor Platzbecker’s presentation at EHA 2024 include1:
-
The primary endpoint, of two-year event free survival (EFS), was met with an EFS rate of 88% in the ATRA-ATO cohort and 70% for ATRA-CHT (p = 0.02).
-
Five-year overall survival was higher in the ATRA-ATO cohort at 93% versus 82% in the ATRA-CHT cohort (p = 0.17).
-
Two-year incidence of relapse was significantly higher in patients treated with ATRA-CHT at 14% compared with 1.6% for ATRA-ATO (p = 0.011).
-
The incidence of complete remission (CR) or CR with incomplete recovery was not significantly different between the two cohorts (it was numerically higher in the ATRA-ATO cohort at 93% versus 90% with ATRA-CHT (p = 0.654)).
-
There was no increased risk of early mortality with the novel ATRA-ATO regimen.
-
Data presented support the implementation of the ATRA-ATO regimen as a first-line therapy in high-risk APL.
- Platzbecker U. First results of the APOLLO trial: a randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia. Oral abstract #S102. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.
Your opinion matters
3 votes - 20 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox